Research & Development
US Food and Drug Administration grants label update to Novartis' Cosentyx
12 February 2018 -

The US Food and Drug Administration (FDA) has granted approval to Switzerland-based Novartis for its Cosentyx (secukinumab) label update to include moderate-to-severe scalp psoriasis, it was reported on Friday.

The updated label covers Cosentyx data in moderate-to-severe scalp psoriasis, a difficult-to-treat form of the disease, which affects around half of all psoriasis patients. The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.

Kristian Reich of Georg-August-University Gottingen and Dermatologikum Hamburg said, 'Scalp psoriasis is on a very sensitive, and a very visible area of the body. For patients this could translate into physical pain, frustration and social isolation. Patients and doctors are in need of effective treatment options in this and other difficult-to-treat forms of psoriasis.'